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Abstract
Introduction—Primary ciliary dyskinesia (PCD) is a genetically heterogeneous recessive 
disorder resulting in chronic oto-sino-pulmonary disease. While PCD is estimated to occur in 1 in 
20,000 individuals, fewer than 1,000 patients in the US have a well-established diagnosis.
Areas Covered—We provide an overview of the clinical manifestations of PCD, describe the 
evolution of diagnostic methods, and critique the literature on management of PCD.
Expert Opinion—Although interest in clinical studies in non-CF bronchiectasis has increased in 
recent years, some of whom enroll patients with PCD, the literature regarding therapy for PCD as 
a distinct entity is lacking, as the numbers are small, and there have been no sub-analyses 
published. However, with improved screening and diagnostic methods, the development of 
clinical and research consortiums, and actively enrolling registries of PCD patients, the 
environment is conducive to perform longitudinal studies of disease course and therapeutic studies 
to alter that course.
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1. Introduction
Primary ciliary dyskinesia (PCD) [OMIM #244400] is a genetically heterogeneous recessive 
disorder of motile cilia resulting in neonatal respiratory distress, chronic oto-sino-pulmonary 
disease, and male infertility; organ laterality defects are present in approximately 50% of 
individuals1–5. Initially recognized in 1933, the triad of chronic sinusitis, bronchiectasis, and 
situs inversus was termed Kartagener syndrome6. It was not until 1976 when Afzelius 
described the cilia in these patients as being immotile due to defective ciliary ultrastructure7 
that some understanding of the etiology of the syndrome was obtained. Subsequent studies 
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have revealed that cilia have a stiff, or even vigorous, but always uncoordinated and 
ineffective beat consistent with dyskinesia, rather than complete immotility. The term 
“primary” distinguishes it from secondary or acquired (i.e. non-genetically determined) 
ciliary defections associated with infection and inflammation.
Limitations imposed by hitherto inadequate diagnostic methods have made it difficult to 
determine the true prevalence of PCD. Based on population surveys of situs inversus and 
bronchiectasis in Norway and Japan, the incidence of PCD is estimated at 1 per 10,000–
20,000 births8, 9. In the US, there are fewer than 1,000 patients with a well-established 
diagnosis of PCD5. The development and validation of nasal nitric oxide (nNO) as a 
screening test for PCD10 and continued discoveries of PCD causing mutations have 
improved diagnostic certainty5. At this time, there is no therapy specific for PCD; rather 
therapies are extrapolated from other suppurative lung diseases such as cystic fibrosis (CF) 
and non-CF bronchiectasis.
1.1 Cilia structure and function in health and disease
Cilia classification in vivo is based on function, creating two categories: motile and sensory. 
Normal motile cilia contain 9 outer doublets and a central pair (Figure 1). The outer doublets 
are composed of microtubules of α- and β-tubulin monomers, and possess outer and inner 
dynein arms along their length, which contain enzymes for ATP hydrolysis, producing 
ciliary movement. Stability is provided by the nexin links connecting the outer doublets and 
by the radial spokes that extend from the doublets to the central pair. Mutations of genes that 
encode any of these components, or those are involved in the cilia assembly mechanism, 
result in clinical disease. Specialized motile cilia, which lack a central pair, move in a 
rotatory fashion and are responsible for organ lateralization during embryogenesis, hence 
organ laterality defects are associated with some (approximately 50%) patients with PCD.
A single non-motile sensory cilium is present in most cells of the body and contains 
specialized proteins and receptors, which sense the local environment. This gives the 
sensory cilia an important role in signaling pathways and planar cell polarity. Mutations in 
genes involved in the assembly and function of the sensory cilia result in disorders such as 
Bardet-Biedl syndrome, retinitis pigmentosa, Joubert syndrome, nephronophthisis, and 
autosomal dominant polycystic kidney disease. For the purposes of this review, we will not 
further address these clinical entities.
2. Diagnosis (Figure 2)
A consistent clinical phenotype should prompt a referral to a specialized center for further 
testing. See next section, but briefly, these include neonatal respiratory distress, persistent 
cough or recurrent pneumonias from birth, recurrent difficult otitis media, and/or 
unexplained bronchiectasis in adulthood. The presence of situs inversus or ambiguous, or 
male infertility and female subfertility in association with the above are particularly 
suggestive of the likelihood of PCD. Unlike CF, digestive tract abnormalities (pancreatic 
insufficiency, liver disease, malnutrition) are not usually a feature of PCD. While some 
features can be seen in isolation in the general population (even situs inversus alone), 
persistence of hallmark clinical features is highly suggestive of PCD. Because PCD 
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diagnostic testing is expensive and requires expertise, identification of clinical 
manifestations of PCD is critical to initiate further diagnostic evaluation at specialized 
centers. Other etiologies of bronchiectasis, including CF, primary immune deficiencies, and 
alpha1-antitrypsin deficiency, should be ruled out. Since motile cilia are present throughout 
the respiratory tract (the conductive airways, paranasal sinuses, middle ear), the clinical 
features of PCD reflect defects in the primary innate defense mechanism of mucociliary 
clearance, which confers much of the morbidity of PCD on patient’s quality of life (cough 
with recurrent infections). Laterality defects result from defects in the embryonic nodal 
motile cilia during embryogenesis. Manifestations of PCD are evident at birth and persist 
through the individual’s lifetime (Table 1).
2.1 Clinical presentation
Neonatal respiratory distress, often described as transient tachypnea of the newborn or 
neonatal pneumonia, is seen in over 80% of term neonates with PCD. Infants have 
tachypnea, increased work of breathing, and may even need supplemental oxygen or 
positive pressure ventilation11–13. This phenomenon implies that cilia in the airways are 
necessary for the clearance of fetal fluid from the lungs.
Daily wet cough, chronic nasal congestion, and recurrent otitis media are nearly universally 
present in PCD patients11, 14. Recurrent otitis media can result in hearing loss and speech 
delays. Chronic sinusitis is seen more often in older children and adults as compared to 
young children secondary to lack of radiographic imaging5. Atelectasis and lobar collapse, 
particularly of the middle and lower lobes, is seen in infants and young children with 
PCD11, 14, 15. Bronchiectasis is universally present in adults with PCD; young children with 
PCD can have airway wall thickening and bronchiectasis visible on high resolution chest 
CT15–17. Evidence of airflow obstruction may be evident on spirometry18, even in young 
children19.
Microbial pathogens in PCD tend to parallel those seen in CF. While Haemophilus 
influenza, Staphylococcus aureus, and Streptococcus pneumoniae dominate the pulmonary 
bacteriology of children with PCD, Pseudomonas aeruginosa is seen in teens and young 
adults11, 20. Chronic Pseudomonas tends to present at a later age as compared to CF, and S. 
pneumoniae is seen more often in PCD than in CF. Similar to CF, some patients culture 
more than one type of bacteria from the same sample. The prevalence of non-tuberculous 
mycobacterium (NTM) in adult PCD patients is about 15% and is somewhat lower in PCD 
children, similar to what is seen in CF20. These observations underscore the need to monitor 
sputum microbiology (including NTM) on a regular basis (at least twice a year).
Cilia also play a critical role in cardiac development and organ lateralization21–23. Situs 
inversus totalis occurs in about 50% of PCD patients. Situs ambiguous occurs in about 12% 
of PCD patients, and manifestations include polysplenia (left isomerism), asplenia (right 
isomerism), duplication of the inferior vena cava, and complex congenital heart 
disease24–26. The risk of structural congenital heart disease in PCD patients with situs 
ambiguous is at least 200-fold higher than the general population with heterotaxy25.
Daniels and Noone Page 3













Due to dysmotility of the spermatozoa flagella, nearly all males with PCD are infertile. 
There are rare reports of men with PCD who have fathered children with27 and without 
fertility assistance28. PCD females have impaired ciliary function within the fallopian tubes, 
which delays ovum transit and can result in ectopic pregnancies or infertility29.
2.2 Nitric oxide measurements for screening and diagnosis
The saccharine test was the first screening test for PCD, but due to the lack of specificity 
and the development of more accurate diagnostic methods, there is no role for this testing in 
the diagnosis of PCD. The observation in the early 1990s that nitric oxide levels in exhaled 
nasal air is lower than that of healthy or disease controls was fortuitous, and has led in recent 
years to the development of measures of nasal NO as a diagnostic test30. Nasal nitric oxide 
(nNO) is appropriate to screen for PCD in patients with a compatible clinical phenotype and 
in whom testing has excluded CF20, 31. In PCD, nNO values are typically 10–20% of normal 
(20.7 nl/min) but individuals with RSPH1 mutations can have higher nNO (98.3 nl/min)32. 
Using a standardized protocol, a disease specific cutoff of 77nl/min has a sensitivity of 98% 
and a specificity of >99.9%. The positive predictive value is influenced by age and 
prevalence, underscoring the importance of obtaining a detailed clinical phenotype3. While 
the test requires some equipment and technical training/expertise, it is easy to perform down 
to about age 5 years, and is non-invasive10. Nasal NO has replaced the saccharine test as a 
reliable screening method.
2.3 Ciliary ultrastructure and ciliary beat
Assessment of ciliary ultrastructure using electron microscopy (EM) has long been 
considered the PCD diagnostic standard, but this method is limited for several reasons. At 
least 30% of patients with PCD have normal ultrastructure33, 34. Furthermore, the challenges 
of obtaining an adequate sample, the technical skill required for sample processing, and the 
experience necessary to correctly interpret the images impose additional limitations. As 
many as 15 to 20% of patients referred to the Genetic Disorders of Mucociliary Clearance 
Consortium (GDMCC) with a diagnosis of PCD based on EM findings did not have PCD5, 
underscoring the importance of this testing occurring in specialized centers.
Assessment of ciliary motility, including beat frequency and waveform analysis, in 
experienced hands, can be a useful adjunct to diagnose PCD, particularly if the patient has 
complete immotility or gross dysmotility of all cilia. Some forms of PCD have subtle or no 
evidence of abnormal beat or waveform. Secondary ciliary dyskinesia can result from 
infection and inflammation, increasing the rate of false positive diagnoses when using 
biologic assessments of ciliary structure and function. Thus, relying on ciliary structural and 
functional analyses alone, as has traditionally been the practice, does not provide enough 
specificity nor sensitivity for the diagnosis of PCD.
2.4 Genetics (Table 2)
The number of genes and mutations identified as causative for PCD has exploded in recent 
years, allowing a shift away from a biological method of diagnosing the disease and towards 
a more definitive method of diagnosis (Table 2)34. Over 65% of PCD patients have biallellic 
mutations identified in one of the 32 published PCD genes5. Continued identification of 
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genetic mutations that result in PCD will provide better understanding of the genotype-
phenotype relationship and more clearly define the phenotypic spectrum of disease. For 
examples, mutations in genes that code for proteins in the ODA complexes result in situs 
abnormalities; this is not seen with mutations in radial spoke head protein genes due to the 
unaffected nodal cilium (which lacks the central pair, and thus retains the normal rotatory 
function important for normal L-R asymmetry). Individuals with mutations in RSPH1 have a 
milder clinical phenotype and higher nNO measures as compared to other PCD patients32. A 
recent publication notes the presence of PCD in patients Cri du Chat Syndrome (CdCS) who 
are hemizygous for a DNAH5 mutation due to the 5p segmental deletion attributed to CdCS 
on the opposite chromosome35.
3. Disease management
Randomized clinical trials in the PCD population are lacking, and publications of therapies 
in PCD mainly consist of case reports. Studies of non-CF bronchiectasis often do not 
indicate if patients with PCD are included, or if they were, how the diagnosis was made. 
Children with non-CF bronchiectasis are not generally included in non-CF studies. Thus, 
therapies for PCD are largely extrapolated from other diseases with defective mucociliary 
clearance, such as cystic fibrosis (CF) and non-CF bronchiectasis. For the purposes of this 
review, we will address and discuss existing as well as novel treatments that have been 
studied in the published literature, and review how these treatments might be useful in PCD. 
The assumption is made that while PCD is a disease associated with defective ciliary 
function, there are no other complications related to systemic manifestations, and that 
treatments shown to be useful in CF and non-CF bronchiectasis may therefore be 
extrapolated to PCD.
The three major focus areas to date are: airway clearance, infection control, and minimizing 
inflammation. Unlike the situation in CF where approaches have been studied to rectify the 
basic defect in the disease using gene therapy, and more recently molecular modulators, no 
such novel strategies have yet been tested in PCD.
3.1 Airway clearance: Devices and pharmacologic approaches (Table 3)
Normal mucociliary clearance, a critical component of airway host defense, occurs when the 
coordinated beating of motile cilia propel the airway surface liquid toward larger airways, 
expelling infectious and non-infectious particles out of the lungs. Alterations in the airway 
surface liquid, such as dehydration as seen in CF, and ineffective ciliary beating as seen in 
primary ciliary dyskinesia, markedly impair this process, leading to clinical disease36–38. 
This leaves mucus, irritants, and infection in the airways, resulting in increased 
inflammation and scarring, ultimately causing bronchiectasis. Therefore, it is imperative to 
augment airway clearance and avoid cough suppressing medications1.
There are a variety of devices and methods available for airway clearance with no clear 
superiority shown for one over others. Intra-thoracic oscillatory devices generate oscillating 
positive pressure through a mouthpiece, resulting in vibrations that shake the mucus off the 
airway walls and intermittent elevation of endobronchial airway pressures that stent the 
airways open for more effective clearance. Airflow accelerations during exhalation mobilize 
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the freed mucus into the larger airways39, 40. Some of these devices connect to a nebulizer, 
allowing patients to inhale a medication and generate oscillations on exhalation. High 
frequency chest compression using vest therapy generate extra-thoracic oscillations at 
variable frequencies and intensities, which are transmitted to the airways39, 41. Other 
methods of airway clearance avoid the use of devices and include manual chest 
physiotherapy, postural drainage, autogenic drainage, active cycle breathing, and 
exercise41–43. Use of one method does not preclude use of another method, even in 
combination44. At this time, there is no clear evidence that one device or method is superior 
to another,45, 46 although one study in children with PCD found that exercise was a more 
potent bronchodilator than inhaling a β2-agonist47.
Another method of removing airway secretions is through airway hydration via aerosolized 
therapies, particularly when secretions are inspissated. In an early pilot study including 
solely PCD patients, aerosolized uridine-5′-triphosphate (UTP), which acts to increase 
chloride secretion (and thus water) across airway epithelia, significantly increased airway 
clearance as measured using clearance of radiolabeled particles during cough. Although an 
increase in ciliary beat would not be expected in PCD (unlike in healthy controls), UTP 
increased chloride conduction into the airway via an alternative channel, altering the liquid 
and mucin content within airway secretions, thus facilitating cough clearance48. Along 
similar lines, several studies have tested whether isotonic saline (0.9%) or hypertonic saline 
(3 or 7%) improves airway clearance in non-CF bronchiectasis. A small study in non-CF 
bronchiectasis patients demonstrated improved clearance after nebulizing isotonic saline 
prior to chest physiotherapy49. Prior to research demonstrating improved airway clearance in 
CF patients after nebulizing hypertonic saline, evidence emerged that nebulizing hypertonic 
saline was beneficial in non-CF bronchiectasis. Nebulizing hypertonic saline 7% resulted in 
significantly reduced sputum viscosity, increased ease of expectoration, and therefore, 
increased sputum volume expectorated as compared to isotonic saline. Small but significant 
improvements in lung function were also described50. After three months, individuals with 
non-CF bronchiectasis using hypertonic saline daily had decreased antibiotic use, lower 
health care utilization, and improved quality of life measures. There was continued 
improvement in sputum viscosity, ease of expectoration, and lung function51. In contrast, 
other studies have found no difference in exacerbation frequency, sputum colonization, lung 
function or quality of life after nebulizing hypertonic saline 6% or isotonic saline for 12 
months52. As an example of why this might be, hypertonic saline is thought to disrupt the 
interactions between IL-8 and glycosaminoglycans. This makes IL-8 more susceptible to 
degradation, thereby limiting the concentrations of this pro-inflammatory cytokine within 
the airway53. The differing impact of hypertonic saline54 may relate to individual variation 
in airway IL-8 levels as well as the underlying cause of the bronchiectasis. Based on two 
studies which found significantly higher levels of IL-8 in sputum expectorated from children 
with PCD as compared to children with CF55, 56, PCD patients may have a greater potential 
to derive benefit from inhaled hypertonic saline, and deserves further study in this 
population.
Recombinant human DNase I (rhDNase, dornase alfa) provides significant benefit in CF57, 
leading some to propose benefit in non-CF bronchiectasis. In the setting of infection, 
neutrophils accumulate in the airways and undergo necrosis; DNA and actin are released and 
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increase sputum viscosity58–60. Recombinant human DNase I cleaves extracellular DNA, 
decreasing the DNA concentration, and thereby decreasing sputum viscosity. There are 
several case reports noting improvement in pulmonary symptoms in PCD patients with both 
intermittent61 and chronic use62, 63. Although PCD airway secretions contain elevated DNA 
concentrations55, it is not to the same degree as CF. Importantly, a randomized control trial 
found that dornase alfa provided no benefit and potentially cause harm when used by 
idiopathic bronchiectasis patients64. It is unclear how many well-phenotyped PCD patients 
were enrolled in this study. For the present, inhaled dornase alpha is not recommended for 
patients with non-CF bronchiectasis, including PCD.
Inhaled mannitol increases mucociliary and cough clearance in patients with asthma, 
bronchiectasis, and CF by creating an osmotic drive for water to move into the airway and 
hydrate secretions65. In cell culture, mannitol increases ciliary beat frequency66. This 
therapy may be beneficial in PCD patients through improved cough clearance as it is 
unlikely to improve ciliary beat without correcting the underlying structural defect. In a 
recent publication of non-CF bronchiectasis patients, inhaled dry powder mannitol (400 mg 
twice daily) over 52 weeks did not decrease annual exacerbation rates (primary outcome) 
nor improve FEV1 but did increase the time to exacerbation and improved quality of life 
measures67. Overall, it was well tolerated with similar mild and moderate adverse event 
frequency to the placebo arm; the treatment arm had less frequent severe adverse events as 
compared to the control arm.
N-acetylcysteine (NAC) is a sulfhydryl compound that depolymerizes mucus in vitro by 
breaking the disulfide bonds, decreasing sputum viscosity. Because inhaling NAC can result 
in bronchospasm in patients with hyperresponsive airways and it possess a distasteful sulfur 
smell, it is typically taken orally. Unfortunately, there is no evidence that oral NAC reaches 
therapeutic concentrations in airway secretions68. Additionally, a small study of oral NAC in 
PCD patients found no improvement in clinical status or lung function69.
Because nNO is low in PCD and NO plays a key role in host defense and up-regulation of 
ciliary motility, arginine, a precursor to nitric oxide (NO) synthesis, was postulated to have a 
therapeutic role in PCD. Despite encouraging preliminary data of nasal ciliary motility70, 
arginine did not normalize airway nitric oxide concentrations nor improve lung function71.
3.2 Infection control
Recommendations from the European Respiratory Society and British Thoracic Society 
suggest that clinicians monitor airflow mechanics (spirometry) and collect respiratory 
cultures, including those for NTM, regularly (every 3 to 6 months) in patients with PCD1, 72. 
Specimens should be processed in the same manner as CF sputum, given the similar 
microbial pathogens11, 20. Nebulizer equipment and airway clearance devices should be 
cleaned and disinfected according to CF guidelines.
3.21 Acute anti-microbial therapy—Manifestation of a bronchiectasis exacerbation 
includes an increase in sputum volume or change in sputum viscosity; an increase in sputum 
purulence; and an increase in cough, wheeze, and dyspnea72. Sputum should be sent for 
culture but should not delay initiation of antibiotics, whether oral or intravenous72. Prior 
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sputum culture results can help guide antibiotic choice. Management of the various microbes 
that usually occur in bronchiectasis including PCD (gram negatives, resistant Staph, fungi, 
and NTM) is beyond the scope of this article, and the reader is referred to published 
guidelines72–74. In general, there is little evidence supporting combination antibiotic therapy 
in the absence of P. aeruginosa. There is some controversy as to whether combination 
antibiotics are necessary in patients colonized with P. aeruginosa. The addition of inhaled 
tobramycin to oral ciprofloxacin during exacerbations improved microbial outcomes, but 
clinical outcomes were no different than treating with oral ciprofloxacin alone75. The 
optimal length of antibiotic treatment is unknown; the BTS guidelines recommending 14 
days of treatment is based on grade D evidence72.
3.22 “Preventive” (chronic) anti-microbials—There is no firm evidence as to when to 
initiate such treatment, but clinical experience suggests that inhaled antibiotics for 
prophylaxis should be considered in cases requiring repeated courses of oral antibiotics76, 
particularly if adequate airway clearance is being performed. It is unlikely that patients who 
are non-compliant with airway clearance will regularly use inhaled antibiotics. The use of 
rotational oral antibiotics for long-term outpatient therapy is not recommended routinely72. 
In the US, tobramycin, aztreonam, and colistin are available in a nebulized form, although 
are not FDA approved for use in non-CF bronchiectasis as yet. Ciprofloxacin (liposomal and 
powder preparations), gentamicin, and liposomal amikacin are being tested in clinical trials 
in international studies. Inhaled tobramycin is both tolerable and beneficial in stable adult 
non-CF bronchiectasis patient with chronic Pseudomonas infection77–79. The benefit of 
inhaled aztreonam80, colistin81, and gentamicin82 is less clear (Table 3). Two phase 2 
clinical trials of inhaled ciprofloxacin have shown tolerability with significant reductions in 
total bacterial load and longer time to first exacerbation83, 84.
3.3 Anti-inflammatory approaches
Previously extrapolated from CF literature, the use of macrolides to decrease airway 
inflammation in idiopathic bronchiectasis has recently been examined in several studies. The 
EMBRACE trial in New Zealand found that azithromycin 500 mg taken three days per week 
reduced exacerbation frequency in adults with idiopathic bronchiectasis who experienced at 
least one exacerbation in the preceding year. The number of individuals who cultured 
Pseudomonas or who carried a diagnosis of PCD is unknown85. In idiopathic bronchiectasis 
patients with at least two exacerbations in the previous year, the BLESS trial demonstrated 
that twice daily erythromycin ethylsuccinate significantly reduced exacerbations in all 
enrolled patients and in the pre-specified subgroup with baseline Pseudomonas airway 
infection86. Daily azithromycin 250 mg reduced infectious exacerbation in patients with at 
least three lower respiratory infections in the preceding year in the BAT trial87. Three and 
one PCD patient were enrolled in the BLESS and BAT trials respectively. In contrast to CF, 
most of the non-CF bronchiectasis patients cultured bacteria other than P. aeruginosa, 
suggesting that the mechanism of azithromycin may be both anti-inflammatory and anti-
microbial. Patients should not receive chronic oral macrolides unless they have been tested 
and proven to not have sputum colonized or infected with NTM5. Overall, it appears that 
chronic use of a macrolide provides benefits in patients with non-CF bronchiectasis, 
including patients with PCD. Not all patients with PCD should automatically be prescribed 
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macrolides. In addition to those that may sporadically or chronically expectorate NTM, there 
are those in whom the potential for side effects (cardiac or gastrointestinal) may exceed the 
benefits described above, and there are patients with a good quality of life in whom 
macrolides can be considered in the future.
The use of inhaled corticosteroids, beta-agonists, leukotriene inhibitors, and oral 
corticosteroids should be considered in individuals with overlapping atopic disease72, 88. 
There is no clear evidence that use of these agents benefits all patients with PCD5, 72, 74. 
However, since asthma and allergies are common, they can be present in addition to PCD. 
Before adding beta-agonists to a treatment regimen, it should be noted that PCD patients can 
have spirometry measures that meet ATS criteria for repeatability but improve steadily due 
to cough clearance. If the patient has not reached a plateau during the pre-bronchodilator 
testing, one may erroneously assume that there is a post-bronchodilator response rather than 
attributing improvement to continued cough clearance.
Statins have effects beyond reducing cholesterol levels, including reducing inflammation 
and modulating the innate and adaptive immune systems. A recent publication demonstrated 
improvement in the Leicester Cough Questionnaire, a quality of life measurement 
instrument, in non-CF bronchiectasis patients after 6 months of atorvastatin. Further study is 
needed to determine if long-term statin use can also reduce exacerbations89.
It is critical to avoid exposure to inflammatory triggers. Patients and family members who 
smoke should receive smoking cessation counseling. Routine immunizations including 
influenza, pneumococcus, and pertussis should be encouraged1, 5.
3.4 Other management methods
Since PCD is a disease that affects cilia throughout the entire lung, lobectomy should be 
carefully considered and is rarely indicated. Patients in whom lobectomy should be 
considered include those with severe localized bronchiectasis with recurrent febrile relapses 
despite aggressive therapy and those with uncontrolled severe hemoptysis90. PCD patients 
with end stage lung disease are candidates for lung transplantation. A small number have 
been successfully performed in PCD patients, both with and without situs inversus91.
3.5 Upper airway disease
The management of ear and nose disease is similar to the management of lung disease. Sinus 
rinses augment clearance of mucus from the nasal passages and sinuses1. Antibiotic rinses 
have been used to treat persistent bacterial colonization in PCD. Nasal steroids can be 
helpful in patients with significant allergic rhinitis and sinusitis. In patients with sinus 
disease refractory to medical management, functional endoscopic sinus surgery is helpful, 
particularly if there is aggressive postsurgical treatment to maintain adequate drainage92. 
Tympanostomy tube placement is controversial. Although tubes may improve hearing93, 
otitis media can improve during the teen years, and tubes may result in persistent otorrhea94. 
Because conductive hearing loss due to chronic otitis media can result in speech and 
language development delay, audiology assessments, hearing aids, and adjunctive therapies 
should be encouraged1.
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In conclusion, primary ciliary dyskinesia is a genetically heterogeneous recessive disorder of 
motile cilia which results in chronic oto-sino-pulmonary disease. Diagnostic methods have 
advanced to now include nNO as a screening test in individuals with a compatible clinical 
phenotype and other known causes of bronchiectasis and chronic oto-sino-pulmonary 
disease have been excluded. Ciliary ultrastructural abnormalities as seen on electron 
microscopy and videomicroscopy are useful adjunctive diagnostic modalities as the genetic 
mutations involved in PCD are further identified. Management of PCD is primarily 
extrapolated from studies in cystic fibrosis and non-CF bronchiectasis. The foundation of 
managing disease in PCD includes airway clearance, infection control, and reduction of 
inflammation. With the development of clinical and research consortiums and actively 
enrolling registries of PCD patients, the environment is conducive to initiate longitudinal 
studies of disease course as well as therapeutic trials to alter disease course.
5. Expert Opinion
The method of diagnosing PCD has dramatically changed over the past decade. Through 
large cross-sectional studies, the clinical phenotype of PCD has been refined with better 
definitions and new knowledge, for example, the high prevalence of neonatal respiratory 
distress in PCD, and the association with complex congenital heart disease. It is now known 
that mutations that preserve the ciliary central apparatus do not result in situs abnormalities, 
and that PCD individuals with situs ambiguous are more likely to have complex congenital 
heart disease. Nasal NO has proven to be an excellent screening test for PCD. However, like 
sweat chloride in CF, nNO levels in PCD can include false positives as well as false 
negatives, underscoring the importance of determining the genetic mutations. The diagnosis 
of PCD had hinged on the visualization of ciliary ultrastructural defects on EM, an imperfect 
diagnostic method. At least 30% of individuals with PCD have normal ciliary ultrastructure 
(DNAH11 and CCDC65 mutations). Other mutations result in ultrastructural defects in only 
a subset of cilia; this may not be appreciated without the skill and expertise in sample 
processing and image interpretation. Elucidating genetic mutations for all patients with PCD 
is rapidly becoming a reality. The number of known PCD causing genes has more than 
doubled in the past three years, and a PCD research genetic panel is under development 
through the GDMCC.
Treatment of PCD patients lacks evidence and standardization. Many patients receive sub-
optimal management including lack of sputum cultures and pathogen directed antibiotic 
therapy. The Bronchiectasis Severity Index (BSI) can help clinicians identify patients, 
including those with PCD bronchiectasis, who are at high risk of developing bronchiectasis 
complications and therefore, may benefit from intensification of therapies such as adding 
inhaled antibiotics or oral macrolides95.
Working together, the GDMCC and the PCD Foundation have developed the PCD 
Foundation Clinical and Research Center Network (CRCN), which includes the eight 
original GDMCC sites, four new sites, and nine affiliate sites. The goal of the CRCN is to 
provide a reliable diagnosis; consistent high-quality, appropriate care; and comprehensive 
Daniels and Noone Page 10













data collection through the PCD registry96. BESTCILIA is a research consortium comprised 
of ten European clinical centers and two US clinical centers with the goal of improving the 
clinical practice in PCD care through standardized care protocols and diagnostic testing as 
well as observational and randomized control trials97. The development and validation of a 
PCD quality of life instrument98, 99 leaves researchers well-poised to capitalize on patient 
participation in the CRCN and PCD registry with longitudinal studies to more accurately 
describe disease course and randomized control studies to alter this course.
Therapeutic studies directly assessing the benefit of hypertonic saline, azithromycin, or even 
dornase alfa are potential initial research directions. Looking to the future, given the success 
with modulatory therapeutics for CF, it is conceivable that genetic modulators could 
improve or fully correct ciliary defects in PCD. Extrapolating from the chronic bronchitic 
COPD phenotype, roflumilast may decrease the airway inflammation seen in PCD. A new 
orphan drug candidate, NM001 (Lynovex®; NovaBiotics) is a mucolytic agent being tested 
in CF, and potentially other chronic lung diseases. When considering these types of 
therapeutic trials, it is critical to choose the correct primary outcome. Exacerbation rate was 
a sound outcome in the macrolide studies, given that exacerbations manifest with increased 
inflammation and macrolides are presumably acting as an anti-inflammatory agent. A 
quality of life measurement was used in the atorvastatin trial and reached significance. 
However, quality of life measures and exacerbation frequency have not yielded the same 
outcomes in the inhaled antibiotic studies.
PCD is a genetically heterogenous disease with a variety of mutations in numerous genes 
resulting in a shared phenotype, sparing no race or ethnic group. Despite general 
perceptions, PCD lung disease may not necessarily be mild. A delay in recognizing PCD 
features and formal diagnosis can result in the development and progression of irreversible 
lung disease. In CF, early identification and diagnosis leads to early treatment and frequent 
monitoring to decrease morbidity and mortality. Although CF and PCD are both recessive 
disorders that result in bronchiectasis and sinusitis, the underlying pathogenesis differs. 
While the CF model is appropriate for disease follow up and development of a clinical 
network of disease expertise, PCD is not the same as CF, and management is not 
identical100. This is evidence in prior studies of UTP, which demonstrated improved airway 
clearance in PCD patients but no benefit in CF patients. Without further PCD patients to test 
the therapy, there was little incentive for pharmaceutical companies to pursue drug 
development. Improved identification and more accurate diagnosis of PCD provides a large 
cohort of PCD patients who are eager to participate in research with the goal of improving 
clinical care.
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• Primary ciliary dyskinesia is a genetically heterogeneous recessive disorder of 
motile cilia that results in chronic oto-sino-pulmonary disease as well as organ 
laterality defects and congenital heart disease.
• Nasal nitric oxide is a useful screening test in individuals with a compatible 
clinical phenotype and in whom other known cause of chronic oto-sino-
pulmonary disease have been excluded.
• Although useful, biologic diagnostic methods, such as assessment of ciliary 
ultrastructure using electron microscopy and visualization of ciliary motility 
using videomicroscopy, are limited by technical skill and availability of 
equipment.
• Continued identification of genetic mutations causing PCD provides a more 
definitive diagnostic method. Over 65% of PCD patients have biallelic 
mutations identified in one of the 30 published PCD genes.
• The foundation of managing disease in PCD includes airway clearance, 
infection control, and reduction of inflammation. Use of the Bronchiectasis 
Severity Index can help identify individuals at high risk of complications from 
their bronchiectasis who may benefit from intensification of therapies.
• With the development of clinical and research consortiums and actively 
enrolling registries of PCD patients, the environment is conducive to initiate 
longitudinal studies of disease course as well as therapeutic trials to alter disease 
course.
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Figure 1. Normal motile cilia (9+2) configuration
Reprinted with permission of the American Thoracic Society. Copyright © 2014 American 
Thoracic Society. Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. 
Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J 
Respir Crit Care Med 2013 Oct 15;188(8):913–22. Official Journal of the American 
Thoracic Society.
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Diagnostic algorithm for PCD diagnosis
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Table 1
Clinical Features of Primary Ciliary Dyskinesia





Year-round, daily nasal congestion
Pan-sinusitis
Eustachian Tubes
Chronic or recurrent otitis media
Transient hearing loss
Trachea & Bronchi
Year-round, daily wet cough
Unexplained neonatal respiratory distress
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